Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: Subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 12, 2014, Pages 1670-1675

  Paul, C ^a   Reich, K ^b   Gottlieb, A B ^c   Mrowietz, U ^d   Philipp, S ^e   Nakayama, J ^f   Harfst, E ^g   Guettner, A ^g   Papavassilis, C ^g  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b DERMATOLOGIKUM HAMBURG   (Germany)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; PLACEBO; SECUKINUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOOT; HAND; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAIL; PHASE 2 CLINICAL TRIAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; CLINICAL TRIAL; PATHOLOGY; PSORIASIS;

ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FOOT; HAND; HUMANS; NAILS; PLACEBOS; PSORIASIS;

EID: 84912024938     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12359     Document Type: Article

References (23)

1. Jacobson CC, Kumar S, Kimball AB,. Latitude and psoriasis prevalence. J Am Acad Dermatol 2011; 65: 870-873.
2. Lebwohl M,. Psoriasis. Lancet 2003; 361: 1197-1204.
3. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman S,. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271-275.
4. Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M,. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas 2011; 2: 1-6.
5. de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC,. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193: 300-303.
6. Reich K,. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 15-21.
7. Wozel G,. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008; 26: 448-459.
8. de Vries AC, Bogaards NA, Hooft L, et al,. Interventions for nail psoriasis. Cochrane Database Syst Rev 2013; 1: CD007633.
9. Christophers E, Segaert S, Milligan G, Molta CT, Boggs R,. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J Dermatolog Treat 2013; 24: 193-198.
10. Herrier RN,. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm 2011; 68: 795-806.
11. Au SC, Goldminz AM, Kim N, et al,. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe palmoplantar psoriasis. J Dermatolog Treat 2013; 24: 179-187.
12. Bulai Livideanu C, Lahfa M, Mazereeuw-Hautier J, Paul C,. Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology 2010; 221: 321-323.
13. Di Lernia V, Guareschi E,. Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J 2010; 16: 8.
14. Leonardi C, Langley RG, Papp K, et al,. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147: 429-436.
15. Luger TA, Barker J, Lambert J, et al,. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904.
16. Rigopoulos D, Gregoriou S, Lazaridou E, et al,. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol 2010; 24: 530-534.
17. Rigopoulos D, Gregoriou S, Makris M, Ioannides D,. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 2011; 223: 325-329.
18. Ortonne JP, Paul C, Berardesca E, et al,. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol 2013; 168: 1080-1087.
19. Hueber W, Patel DD, Dryja T, et al,. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
20. Papp KA, Langley RG, Sigurgeirsson B, et al,. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomised, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412-421.
21. Rich P, Sigurgeirsson B, Thaci D, et al,. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402-411.
22. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
23. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.